United-Guardian, Inc. is classed by the SEC under Perfumes, Cosmetics & Other Toilet Preparations (industry code 2844), based in Hauppauge, NY. Its latest filed balance sheet (2025-12-31) shows total assets of $13 million (its filed statements).
Product businessPerfumes, Cosmetics & Other Toilet PreparationsHauppauge, NYfilings since 19958 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2844, Perfumes, Cosmetics & Other Toilet Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.7 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.9 out of ten, present 5.8 out of ten, future 4.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 3.3 out of ten. 3 warning events since 2017; the latest 2023-08-31. 33rd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.0 out of ten. -2.6% a year over 9 filed years; profitable in 9 of 9. 30th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 6.9 out of ten. Share count steady. 70% of cash flow returned. Insiders: 0 sales, 0 purchases. 69th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 7.3 out of ten. ROE 19%: 19¢ of profit per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar. 73rd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.1 out of ten. bottom 41% of 17 in its family; net margin 20%. 41st percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.4 out of ten. CrossAssetData estimate 5.4/10, confidence 20 of 100 (family median). 50th percentile among 11 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 6.4 out of ten. top 36% of 17 in its family for room to expand. 64th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 2.2 out of ten. bottom 22% of 16 in its family for growth drivers. 22nd percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 2.4 out of ten. bottom 24% of 16 in its family for expectations against reality. 24th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-27 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-11 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-07 (on EDGAR). Newest filing: Form 10-Q, 2026-08-11. Filings on record since 1995. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Pharmaceuticals 52%, Cosmetic Ingredients 28%, Medical Lubricants 20%. By geography: United States 77%, Outside the United States 23%. As tagged in its annual report (Form 10-K, filed 2026-03-27).
Who runs it
Globus, Kenneth H (President). 1 officer or director has filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.